drugset / Trial / NCT06554184

HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

NCT06554184

Phase 3 Completed 706 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is aimed to evaluate the efficacy and safety of HR20013 versus palonosetron for nausea and vomiting associated with moderate emetic risk anticancer agents

Timeline

Start
2024-09-03
Primary completion
2025-07-28
Completion
2025-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HR20013 Other / unclassified
Comparator Palonosetron Other / unclassified
Comparator Dexamethasone Small molecule